# OnCo record nct02671435 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct02671435/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct02671435", "NCT02671435" ;
  schema:name "A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors"@en ;
  schema:description "A phase 1/2 trial of Monalizumab, Durvalumab, Cetuximab, FOLFOX (5-FU, leucovorin, oxaliplatin) and Bevacizumab in advanced solid tumours, run by MedImmune LLC, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct02671435/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02671435> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2016-02-22" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/monalizumab/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/cetuximab/>, <https://onco.cc/drugs/folfox/>, <https://onco.cc/drugs/bevacizumab/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> .